Journal article
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
Abstract
BACKGROUND: Half of patients with chronic heart failure (CHF) have preserved left-ventricular ejection fraction (LVEF), but few treatments have specifically been assessed in such patients. In previous studies of patients with CHF and low LVEF or vascular disease and preserved LVEF, inhibition of the renin-angiotensin system is beneficial. We investigated the effect of addition of an angiotensin-receptor blocker to current treatments.
METHODS: …
Authors
Yusuf S; Pfeffer MA; Swedberg K; Granger CB; Held P; McMurray JJ; Michelson EL; Olofsson B; Östergren J; Investigators and Committees FTC
Journal
The Lancet, Vol. 362, No. 9386, pp. 777–781
Publisher
Elsevier
Publication Date
9 2003
DOI
10.1016/s0140-6736(03)14285-7
ISSN
0140-6736
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdolescentAdultAgedAngiotensin Receptor AntagonistsAntihypertensive AgentsBenzimidazolesBiphenyl CompoundsCardiovascular DiseasesDouble-Blind MethodFemaleFollow-Up StudiesHeart FailureHospitalizationHumansMaleMiddle AgedOutcome Assessment, Health CarePlacebosStroke VolumeTetrazolesTreatment OutcomeVentricular Function, Left